Loading...

CLDI CALIDI BIOTHERAPEUTICS INC Capital Structure Changes 8-K Filing

CLD

CLD

CALIDI BIOTHERAPEUTICS INC

(CLDI)

2025 8-K

Show Summary

Show Summary

Financial Statements

Management Change

Securities Offering

Financial Results

Gene Therapy Announcement

Filing Amendment

Share Offering Increase

Equity Agreement Termination

Cancer Treatment Data

Q3 Financial Results

Company Presentation

Warrant Delisting

Annual Meeting Results

Webinar Presentation

New Subsidiary Announcement

Director Departure

Financial Results

Investment and Appointment

Reverse Stock Split

Reverse Stock Split

Appointment of Dr. George P...

Special Meeting of Stockhol...

Entry into Material Definit...

Warrant Exercise and Issuan...

Compensation Adjustments fo...

Resignation of Director

Earnings Report

Presentation Slides

Public Offering

Settlement Agreement Amendment

Settlement Agreement with I...

Financial Results

Settlement Agreement with I...

Bylaws Amendment

Presentation Slides

Unregistered Sales of Equit...

Financial Update

Regulation FD Disclosure

Regulation FD Disclosure

Presentation at Summit

Equity Purchase Agreement

Resignation of Director

Earnings Reports

Employment Agreement with C...

Appointment of Director

Resignation of Director

Merger of Equals

Merger of Equals

Merger Agreement and Financ...

Special Meeting Adjournment

Special Meeting Adjourned

Business Combination Transa...

Press Release and Presentation

Merger Agreement with Calid...

Extension of Business Combi...

Merger Agreement and Amendm...

Merger Agreement and Invest...

Merger Agreement

External Links:

Calidi Biotherapeutics terminated its Standby Equity Purchase Agreement with Yorkville, which allowed for the potential sale of up to $25 million in shares, and reported raising $9.5 million from public offerings and additional funds from warrant exe

AI Assistant

CALIDI BIOTHERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.